Parion Sciences Announces Initiation Of Phase I Clinical Trial To Evaluate Safety And Tolerability Of GS9411

Parion Sciences, Inc. announced that its partner, Gilead Sciences (Nasdaq: GILD), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to increase airway hydration for the treatment of pulmonary disease.

More: continued here

Filed under: Clinical Trials on December 6th, 2008